contact us

targetGroup_clinicianInnovators
targetGroup_ResearchAdministrator
targetGroup_IndustryPartner
targetGroup_Investor

Natriuretic peptide analogues with vasodilatory or renal activities for personalized care of heart failure patients

Heart failure (HF) is a common, costly, frequently fatal condition and the leading cause of hospitalization in people older than 65, HF afflicts 38 million people worldwide and is responsible for ~25% deaths. Because of its earlier onset, new management strategies are needed in Asia. The course of chronic HF is punctuated by recurrent episodes of life threatening acute decompensated HF (ADHF) an abrupt deterioration characterized by hemodynamic instability, and pulmonary oedema, often associated with decline in renal function. Not all HF patients have similar volume–pressure derangement. Two-thirds of ADHF are “warm and wet”, in which arterial pressure and peripheral tissue perfusion are relatively preserved but pulmonary and peripheral edema are present. The critical “cold and wet” state, with volume expansion, pulmonary and/or peripheral edema and relative hypotension and impaired peripheral perfusion, increases the rate of death by 2.5 fold.

Unfortunately, no new therapeutic agents for ADHF have been introduced for 30 years and existing therapies cannot be individualized to treat each phenotype precisely. A major unmet need therefore exists for therapeutic agents allowing controlled vasodilation without excess diuresis, which risks rebound into volume depletion and kidney injury at one end of the spectrum and effective diuresis to remedy volume overload and edema without excess lowering of blood pressure which risks hypo perfusion of vital organs, at the other end.

Project Deliverables

With a long-term intention to provide better treatment for ADHF patients, this team will evaluate two proprietary distinct classes of natriuretic peptide analogues (NPAs) – one with exclusive vasodilatory effects without diuresis and the other with exclusive diuretic effects without vasodilation, in well-established normal and ADHF sheep models as a prelude to first-in-human trials.


Principal Investigator: Prof Mark Richards

Institution: National University Health System

NHIC Ref: NHIC-I2D-1612150

 

 

See all BIOPHARMA projects >

Mobile Interactive Supervised Therapy

Medication adherence in tuberculosis treatment is critical for patient’s cure, infection control...

Development of highly conductive microneedle array for painless dental anaesthesia

Pain management during dental procedures is a cornerstone for successful everyday practice. Curre...

Modular Endoprosthesis for Mandible Reconstruction

Mandible defects may result from trauma, inflammatory diseases or upon tumour resection. The gold...

Novel inhibitors for Natural Killer/T-cell lymphoma (NKTCL)

The Natural Killer/T-cell lymphoma (NKTCL) is a subtype of Non-Hodgkin’s lymphoma (NHL) which is...

Towards a Novel Drug Therapy for Treatment-Resistant Depression: Adjunct 5-HTP Slow-Release

Depression is the leading cause of disability worldwide, and is a major contributor to the global...

Natriuretic peptide analogues for heart failure patients

Natriuretic peptide analogues with vasodilatory or renal activities for personalized care of hear...

OUR PARTNERS

Clinical Partners


nhg logonuhs logosinghealth

 

Academic Partners


lkc medicalnus faculty of dentistrynus sphnus somduke nus

 

Supporting Partners


bms ipodxdipinmrcSCRIseriSMARTEnterpriseSG